Systematic Review of the Cost of Illness of Parkinson's Disease from a Societal Perspective

被引:0
|
作者
Wijers, Anke [1 ,2 ]
Ravi, Anirudhan [1 ]
Evers, Silvia M. A. A. [1 ,3 ]
Tissingh, Gerrit [2 ]
van Mastrigt, Ghislaine A. P. G. [1 ]
机构
[1] Maastricht Univ, Care & Publ Hlth Res Inst CAPHRI, Dept Hlth Serv Res, Maastricht, Netherlands
[2] Zuyderland Med Ctr, Dept Neurol, POB 5500, NL-6130 MB Heerlen, Netherlands
[3] Trimbos Inst, Inst Mental Hlth & Addict, Ctr Econ Evaluat, Utrecht, Netherlands
关键词
Parkinson's disease; cost of illness; societal perspective; Health Technology Assessment; QUALITY-OF-LIFE; ECONOMIC BURDEN;
D O I
10.1002/mds.29995
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Previous reviews on the cost of illness (COI) of Parkinson's disease (PD) have often focused on health-care costs due to PD, underestimating its effects on other sectors. This systematic review determines the COI of PD from a societal perspective. The protocol was registered in PROSPERO (ID: CRD42023428937). Embase, Medline, and EconLit were searched up to October 12, 2023, for studies determining the COI of PD from a societal perspective. From 2812 abstracts, 17 studies were included. The COI of PD averaged <euro>20,911.37 per patient per year, increasing to almost <euro>100,000 in the most severely affected patients. Health-care costs accounted for 46.1% of total costs, followed by productivity loss (37.4%) and costs to patient and family (16.4%). The COI of PD strongly varied between different geographical regions, with costs in North America 3.6 times higher compared to Asia. This study is the first to identify the relative importance of different cost items. Most important were reduced employment, government benefits, informal care, medication, nursing homes, and hospital admission. There was strong variety in the cost items that were included, with 55.2% of cost items measured in fewer than half of articles. Our review shows that PD-COI is high and appears in various cost sectors, with strong variety in the cost items included in different studies. Therefore, a guideline for the measurement of COI in PD should be developed to harmonize this. This article provides a first step toward the development of such a tool by identifying which cost items are most relevant. (c) 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] COST OF ILLNESS OF CHRONIC KIDNEY DISEASE IN LEBANON: FROM THE SOCIETAL PERSPECTIVE
    Aoun, Mabel
    Helou, Elie
    Sleilaty, Ghassan
    Chelala, Dania Nehme
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36
  • [2] The Societal Cost of Schizophrenia: An Updated Systematic Review of Cost-of-Illness Studies
    Claire Lin
    Xiaoyu Zhang
    Huajie Jin
    PharmacoEconomics, 2023, 41 : 139 - 153
  • [3] The Societal Cost of Schizophrenia: An Updated Systematic Review of Cost-of-Illness Studies
    Lin, Claire
    Zhang, Xiaoyu
    Jin, Huajie
    PHARMACOECONOMICS, 2023, 41 (02) : 139 - 153
  • [4] SYSTEMATIC REVIEW OF SOCIETAL COST OF ILLNESS EVIDENCE IN PATIENTS WITH PSORIATIC ARTHRITIS
    King, D.
    Mitchell, S. A.
    Keyzor, I
    Kiri, S.
    VALUE IN HEALTH, 2014, 17 (07) : A378 - A378
  • [5] SYSTEMATIC REVIEW OF SOCIETAL COST OF ILLNESS EVIDENCE IN PATIENTS WITH ANKYLOSING SPONDYLITIS
    King, D.
    Mitchell, S. A.
    Keyzor, I
    Kiri, S.
    VALUE IN HEALTH, 2014, 17 (07) : A378 - A378
  • [6] A systematic review of depression and mental illness preceding Parkinson's disease
    Ishihara, L
    Brayne, C
    ACTA NEUROLOGICA SCANDINAVICA, 2006, 113 (04): : 211 - 220
  • [7] COST OF ILLNESS OF NEUROPATHIC PAIN IN SPAIN IN 2012 FROM A SOCIETAL PERSPECTIVE
    Ruiz, L.
    Liedgens, H.
    Obradovic, M.
    VALUE IN HEALTH, 2013, 16 (07) : A381 - A381
  • [8] PARKINSON'S DISEASE EXPERIENCE FROM A PATIENT'S PERSPECTIVE: SYSTEMATIC REVIEW ON PATIENT REPORTED OUTCOMES
    Shah, P.
    Yuan, J.
    VALUE IN HEALTH, 2020, 23 : S276 - S276
  • [9] Parkinson's disease experience from a patient's perspective: Systematic review on patient reported outcomes
    Shah, Priti
    Dilley, Anne
    Yuan, Jing
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 290 - 290
  • [10] Cost of illness of atopic dermatitis in children - A societal perspective
    Kemp, AS
    PHARMACOECONOMICS, 2003, 21 (02) : 105 - 113